Feed ALKLH.PA
Summary
55 / 100 · Bulios Score
Valuation 47Growth 100Profitability 46Quality 25Debt 83Stability 34
What speaks for it
- Revenue grew by 34% a year over the last 3 years.
- It could repay all its net debt from 1.0 years of operating profit.
What to watch
- The share price is above the Bulios Fair Price.
- It earns only 4.0 EUR a year on every 100 EUR of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price
Current price 0.12 €
Medical - Diagnostics & Research industry median
P/E today 25.9
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 25.9 EUR for 1 EUR of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (EUR)
202020212022202320242025
Diluted EPS (EUR)
20202021202220232024
- Analyst estimate
Revenue grew by 34% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Cash and short-term investments 5.25M €
Debt 5.37M €
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail